Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of chemotherapy"
DOI: 10.1080/1120009x.2025.2561969
Abstract: The rise of immunotherapies, particularly PD-L1 inhibitors like avelumab, has advanced cancer care, but its pulmonary safety profile remains unclear. Using FAERS data from 2013-2023, we evaluated respiratory complications linked to avelumab through disproportionality analysis… read more here.
Keywords: adverse events; ror; characterizing pulmonary; avelumab ... See more keywords
Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system.
Sign Up to like & getrecommendations! Published in 2025 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2025.2499218
Abstract: BACKGROUND The emergence of monoclonal antibodies has notably enhanced the outcomes for multiple myeloma. However, comprehensive assessment of monoclonal antibody-related pulmonary adverse events remains scarce. RESEARCH DESIGN AND METHODS This pharmacovigilance study analyzed adverse event… read more here.
Keywords: adverse events; pneumonia; pulmonary adverse; adverse event ... See more keywords
The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid‐related diseases: An analysis of the national pharmacovigilance database in South Korea
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Digestive Diseases"
DOI: 10.1111/1751-2980.13075
Abstract: The objective of this case/non‐case study was to detect rebamipide‐related pulmonary adverse events (AE) compared with other drugs for acid‐related disorders based on population‐level data. read more here.
Keywords: drug reactions; pulmonary adverse; drugs acid; adverse drug ... See more keywords
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components
Sign Up to like & getrecommendations! Published in 2022 at "Transfusion"
DOI: 10.1111/trf.16987
Abstract: Platelet transfusion carries risk of transfusion‐transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion‐related acute lung injury and acute respiratory distress syndrome (ARDS) occur… read more here.
Keywords: platelet; platelet components; pulmonary adverse; risk ... See more keywords